Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

New England Journal of Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 25, 2024

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits pathway.

Language: Английский

---

Exploring Novel Adverse Events of Nefecon

Kidney International Reports, Journal Year: 2024, Volume and Issue: 9(9), P. 2705 - 2717

Published: July 6, 2024

Nefecon, the first innovative drug approved by both US Food and Drug Administration (FDA) European Medicines Agency for IgA nephropathy (IgAN), lacked comprehensive real-world assessments of its adverse events (AEs).

Language: Английский

---

IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis

Pediatric Nephrology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 27, 2024

Language: Английский

---

Circulating Proteins and IgA Nephropathy

Journal of the American Society of Nephrology, Journal Year: 2024, Volume and Issue: 35(8), P. 1045 - 1057

Published: April 30, 2024

Key Points A multiancestry proteome-wide Mendelian randomization analysis was conducted for IgA nephropathy. The findings from the study would help prioritize new drug targets and drug-repurposing opportunities. Background therapeutic options nephropathy are rapidly evolving, but early diagnosis targeted treatment remain challenging. We aimed to identify circulating plasma proteins associated with by studies across multiple ancestry populations. Methods In this study, we applied colocalization analyses estimate putative causal effects of 2615 on in Europeans 235 East Asians. Following two-stage network randomization, multitrait protein-altering variant annotation were performed strengthen reliability results. protein–protein interaction constructed investigate interactions between identified existing medications. Results Putative 184 13 protein–disease pairs European Asian ancestries identified, respectively. Two showed shared them (CFHR1 FCRL2). Supported evidence analysis, potential prioritized four opportunities suggested. further provided strong medications pathways that known be therapeutically important. Conclusions Our a number several require investigation.

Language: Английский

---

Therapy of IgA nephropathy: time for a paradigm change

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Aug. 15, 2024

Immunoglobulin A nephropathy (IgAN) often has a poor outcome, with many patients reaching kidney failure within their lifetime. Therefore, the primary goal for treatment of IgAN should be to reduce nephron loss from moment diagnosis. To achieve this, must recognized and treated as both chronic disease an immunological disease. Agents that have received US Food Drug Administration European Medicines Agency approval include modified-release/targeted-release formulation budesonide (Nefecon) sparsentan, selective dual endothelin-A angiotensin II receptor type 1 antagonist. Other agents, including endothelin antagonists, or combined APRIL BAFF vast array complement inhibitors are being investigated IgAN. Furthermore, combinations also studied, sodium–glucose cotransporter-2 antagonists. Due complexity IgAN, combination treatment, rather than single-agent approach, may provide maximum benefit. With number treatments likely increase, allowing safe effective halt progression seem grasp. While trials evaluating ongoing, more needed pave way comprehensive strategy. approach in which agents early rapid induction remission prevent unnecessary irreversible is required. Following remission, adjusted stripped back necessary maintenance phase close monitoring. This review discusses current status explores future strategies improve outcomes

Language: Английский

---

Post-Transplant Glomerulonephritis: Challenges and Solutions

International Journal of Nephrology and Renovascular Disease, Journal Year: 2024, Volume and Issue: Volume 17, P. 81 - 90

Published: March 1, 2024

Glomeruli can be damaged in several conditions after kidney transplantation, with a potential impact on the graft function and survival. Primary glomerulonephritis, group of glomerular immunological damage that results variable histological patterns clinical phenotypes, occur transplant recipients as recurrent or de novo condition. Specific immunologic associated such acute rejection episodes, act an additional trigger impacting incidence these glomerulopathies. The post-transplant GN recurrence ranges from 3% to 15%, varying according subtype time, mainly occurring 3-5 years transplantation. Advances knowledge glomerulonephritis pathophysiology have provided new approaches pre-transplant risk evaluation monitoring. affected by systemic viral infections, human immunodeficiency virus (HIV), hepatitis C (HCV), B (HBV), severe respiratory syndrome coronavirus 2 (SARS-COV-2), cytomegalovirus (CMV), BK virus. diagnosis well identification possible complications them, are important minimize negative impacts recipients' outcomes.

Language: Английский

---

The beneficial effect of adding belimumab in severe and refractory IgA nephropathy: a case report

Pediatric Nephrology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Language: Английский

---

Real-world assessment of sparsentan’s drug safety framework

Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)

Published: Feb. 19, 2025

Background Sparsentan has been approved for reducing proteinuria in adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, yet comprehensive studies evaluating its drug safety framework are lacking.

Language: Английский

---

An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy

Advances in Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 12, 2025

Language: Английский

---

Moderate to severe chronic arteriolar lesions is an independent risk factor for adverse renal outcomes in IgA nephropathy

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0320635 - e0320635

Published: April 24, 2025

Background The impact of chronic arteriolar lesions on the prognosis IgA nephropathy remains controversial. This study aims to explore value varying degrees in predicting patients and analyze associated risk factors that contribute formation. Methods A retrospective analysis was conducted 853 diagnosed with through renal biopsy at Guangdong Provincial Hospital Traditional Chinese Medicine between September 1, 2005, December 31, 2021. Eventually, a total 574 cases were included this study. According degree lesions, divided into four groups: no lesion group (n=115), mild (n=287), moderate (n=131), severe (n=41). Relevant clinical pathological features outcomes recorded. Kaplan-Meier analysis, Cox proportional hazards regression, receiver operating characteristic (ROC) curve utilized examine relationship different nephropathy. Additionally, development identified. Results Worse observed (P<0.05). Moderate (aHR=3.357, 95%CI: 1.018–11.071, P=0.047), creatinine, S1, E1, T2, C2 identified as independent for adverse outcomes. multivariate regression demonstrated lesions. Conclusion independently increases

Language: Английский

---